Literature DB >> 32304110

Dosing will be a key success factor in repurposing antivirals for COVID-19.

Patrick F Smith1, Michael Dodds1, Darren Bentley2, Karen Yeo2, Craig Rayner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32304110     DOI： 10.1111/bcp.14314

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  18 in total

Review 1.  Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?

Authors:  Pascal Le Corre; Gwenolé Loas
Journal:  J Clin Pharm Ther       Date:  2021-03-01       Impact factor: 2.145

2.  Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.

Authors:  Roberto Gomeni; Tianhong Xu; Xuejuan Gao; Françoise Bressolle-Gomeni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-05-20       Impact factor: 2.745

3.  Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.

Authors:  Dan Hartman; Steven Kern; Fran Brown; Suzanne K Minton; Craig R Rayner
Journal:  Clin Transl Sci       Date:  2020-06-11       Impact factor: 4.689

4.  Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.

Authors:  Faryal Khamis; Hanan Al Naabi; Adil Al Lawati; Zaiyana Ambusaidi; Mariam Al Sharji; Umkulthum Al Barwani; Nenad Pandak; Zakariya Al Balushi; Maher Al Bahrani; Issa Al Salmi; Ibrahim Al-Zakwani
Journal:  Int J Infect Dis       Date:  2020-11-09       Impact factor: 3.623

Review 5.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

6.  Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.

Authors:  Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-08-07

7.  Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts.

Authors:  Dario Cattaneo; Mario Corbellino; Cristina Gervasoni
Journal:  Eur J Clin Pharmacol       Date:  2020-11-25       Impact factor: 2.953

8.  Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.

Authors:  Laurent Chouchana; Sana Boujaafar; Ines Gana; Laure-Hélène Preta; Lucile Regard; Paul Legendre; Celia Azoulay; Etienne Canouï; Jeremie Zerbit; Nicolas Carlier; Benjamin Terrier; Solen Kernéis; Rui Batista; Jean-Marc Treluyer; Yi Zheng; Sihem Benaboud
Journal:  Ther Drug Monit       Date:  2021-02-01       Impact factor: 3.118

9.  Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.

Authors:  Aarzoo Thakur; Shawn Pei Feng Tan; James Chun Yip Chan
Journal:  Clin Pharmacol Ther       Date:  2020-10-06       Impact factor: 6.903

10.  Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.

Authors:  Ricardo Peña-Silva; Stephen B Duffull; Andrew C Steer; Sandra X Jaramillo-Rincon; Amanda Gwee; Xiao Zhu
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.